Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1447–1451. doi: 10.1128/aac.37.7.1447

Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.

S R Lavoie 1, E S Wong 1, P E Coudron 1, D S Williams 1, S M Markowitz 1
PMCID: PMC187992  PMID: 8363374

Abstract

Increasing antibiotic resistance in the enterococci, including the capacity for beta-lactamase production and the development of high-level aminoglycoside resistance, has complicated the treatment of serious enterococcal infections, which often require synergistic antibiotic combinations for cure. We utilized the rabbit model of aortic valve endocarditis to investigate the effects of various antibiotics, alone and in combination, against a multiply antibiotic-resistant isolate of Enterococcus faecalis. Female New Zealand White rabbits were infected with either a beta-lactamase-producing, gentamicin-resistant isolate of E. faecalis or a non-beta-lactamase-producing, aminoglycoside-susceptible isolate, and the mean log10 CFU per gram of vegetation were determined. The most active agents were low-dose ampicillin-sulbactam (200 mg/kg of body weight per day), high-dose ampicillin-sulbactam (400 mg/kg of body weight per day), and vancomycin (150 mg/kg of body weight per day), which reduced the titers of bacteria by 2.27, 2.76, and 2.85 log10 (CFU/g, respectively, compared with controls. While ampicillin-sulbactam and vancomycin were equally efficacious in reducing titers of bacteria in vegetations, no animals were cured (defined as < 2 log10 CFU/g of vegetation) by either agent, whether treatment was continued for 3 or 7 days. The addition of gentamicin was not associated with increased killing in rabbits infected with the aminoglycoside-resistant isolate. Both high-dose ampicillin-sulbactam and vancomycin regimens demonstrated significant, continued reduction in bacterial titers with the longer periods of treatment (P < or = 0.05); 7-day treatment with high-dose ampicillin-sulbactam produced a greater reduction in bacterial titers in vegetation than 7-day treatment with vancomycin (P < or = 0.05). We conclude that ampicillin-sulbactam and vancomycin are equally effective in the treatment of experimental endocarditis due to beta-lactamase-producing, highly gentamicin-resistant E. faecalis. The optimum therapy for such infections in humans is not known.

Full text

PDF
1447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coudron P. E., Markowitz S. M., Wong E. S. Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother. 1992 May;36(5):1125–1126. doi: 10.1128/aac.36.5.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eliopoulos G. M., Thauvin-Eliopoulos C., Moellering R. C., Jr Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin. Clin Infect Dis. 1992 Jul;15(1):58–62. doi: 10.1093/clinids/15.1.58. [DOI] [PubMed] [Google Scholar]
  3. Gerberding J. L., Sande M. A. Limitations of animal models in predicting beta-lactam efficacy for endocarditis and meningitis. Rev Infect Dis. 1986 Jul-Aug;8 (Suppl 3):S315–S318. doi: 10.1093/clinids/8.supplement_3.s315. [DOI] [PubMed] [Google Scholar]
  4. Hellinger W. C., Rouse M. S., Rabadan P. M., Henry N. K., Steckelberg J. M., Wilson W. R. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother. 1992 Jun;36(6):1272–1275. doi: 10.1128/aac.36.6.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hindes R. G., Willey S. H., Eliopoulos G. M., Rice L. B., Eliopoulos C. T., Murray B. E., Moellering R. C., Jr Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989 Jul;33(7):1019–1022. doi: 10.1128/aac.33.7.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ingerman M., Pitsakis P. G., Rosenberg A., Hessen M. T., Abrutyn E., Murray B. E., Levison M. E. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis. 1987 Jun;155(6):1226–1232. doi: 10.1093/infdis/155.6.1226. [DOI] [PubMed] [Google Scholar]
  7. Mandell G. L., Kaye D., Levison M. E., Hook E. W. Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med. 1970 Feb;125(2):258–264. doi: 10.1001/archinte.125.2.258. [DOI] [PubMed] [Google Scholar]
  8. Markowitz S. M., Wells V. D., Williams D. S., Stuart C. G., Coudron P. E., Wong E. S. Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Jun;35(6):1075–1080. doi: 10.1128/aac.35.6.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mazzulli T., King S. M., Richardson S. E. Bacteremia due to beta-lactamase-producing Enterococcus faecalis with high-level resistance to gentamicin in a child with Wiskott-Aldrich syndrome. Clin Infect Dis. 1992 Mar;14(3):780–781. doi: 10.1093/clinids/14.3.780. [DOI] [PubMed] [Google Scholar]
  10. Mederski-Samoraj B. D., Murray B. E. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis. 1983 Apr;147(4):751–757. doi: 10.1093/infdis/147.4.751. [DOI] [PubMed] [Google Scholar]
  11. Moellering R. C., Jr, Wennersten C., Weinberg A. N. Synergy of penicillin and gentamicin against Enterococci. J Infect Dis. 1971 Dec;124 (Suppl):S207–S209. doi: 10.1093/infdis/124.supplement_1.s207. [DOI] [PubMed] [Google Scholar]
  12. Murray B. E. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother. 1992 Nov;36(11):2355–2359. doi: 10.1128/aac.36.11.2355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Murray B. E., Mederski-Samaroj B. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest. 1983 Sep;72(3):1168–1171. doi: 10.1172/JCI111042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murray B. E., Singh K. V., Markowitz S. M., Lopardo H. A., Patterson J. E., Zervos M. J., Rubeglio E., Eliopoulos G. M., Rice L. B., Goldstein F. W. Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis. 1991 Apr;163(4):780–785. doi: 10.1093/infdis/163.4.780. [DOI] [PubMed] [Google Scholar]
  15. Patterson J. E., Colodny S. M., Zervos M. J. Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin. J Infect Dis. 1988 Nov;158(5):1144–1145. doi: 10.1093/infdis/158.5.1144. [DOI] [PubMed] [Google Scholar]
  16. Perlman B. B., Freedman L. R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971 Oct;44(2):206–213. [PMC free article] [PubMed] [Google Scholar]
  17. Scheld W. M. Therapy of streptococcal endocarditis: correlation of animal model and clinical studies. J Antimicrob Chemother. 1987 Sep;20 (Suppl A):71–85. doi: 10.1093/jac/20.suppl_a.71. [DOI] [PubMed] [Google Scholar]
  18. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Watanakunakorn C., Bakie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrob Agents Chemother. 1973 Aug;4(2):120–124. doi: 10.1128/aac.4.2.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Watanakunakorn C. Penicillin combined with gentamicin or streptomycin: synergism against enterococci. J Infect Dis. 1971 Dec;124(6):581–586. doi: 10.1093/infdis/124.6.581. [DOI] [PubMed] [Google Scholar]
  21. Wells V. D., Wong E. S., Murray B. E., Coudron P. E., Williams D. S., Markowitz S. M. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med. 1992 Feb 15;116(4):285–292. doi: 10.7326/0003-4819-116-4-285. [DOI] [PubMed] [Google Scholar]
  22. Wolfe J. C., Johnson W. D. Penicillin-sensitive streptococcal endocarditis. In-vitro and clinical observations on penicillin-streptomycin therapy. Ann Intern Med. 1974 Aug;81(2):178–181. doi: 10.7326/0003-4819-81-2-178. [DOI] [PubMed] [Google Scholar]
  23. Yao J. D., Thauvin-Eliopoulos C., Eliopoulos G. M., Moellering R. C., Jr Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1990 May;34(5):827–830. doi: 10.1128/aac.34.5.827. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES